Protara gains as JP Morgan starts at overweight

2026-03-04 10:07:05 ET More on Protara Therapeutics Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Slideshow Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript Protara falls after mid-stage trial data for lead asset in bladder cancer Protara, CeriBell rise on FDA breakthrough designations Read the full article on Seeking Alpha For further details see: Protara gains as JP Morgan starts at overweight